Novo Nordisk receives prestigious accolade from Teleos  

Danish healthcare company Novo Nordisk has been judged a Global Most Admired Knowledge Enterprise by the independent think tank Teleos

Danish healthcare company Novo Nordisk, a world leader in diabetes care, has been judged a Global Most Admired Knowledge Enterprise (MAKE) by the independent think tank Teleos. A panel of Global Fortune 500 senior executives and knowledge experts selected 20 organisations worldwide, of which just two were European based: Unilever (Netherlands/UK) and Novo Nordisk. It is the first time Novo Nordisk has been judged a Global MAKE.

The panel rated the organisations against the MAKE framework of eight key knowledge performance dimensions which are the visible drivers of competitive advantage and intellectual capital growth.

Lise Kingo, Executive Vice President of Novo Nordisk said: "We are very honoured to be singled out for how we work with knowledge. As a world leader in diabetes care Novo Nordisk pursues its aspiration to defeat diabetes while building its business on sustained and balanced growth." The news was reported by financial daily newspaper Børsen and on the Novo Nordisk website.

Novo Nordisk is headquartered in Bagsværd, north of Copenhagen, and employs 22,000 people in 79 countries. The company has the broadest product portfolio in the diabetes industry, including advanced products in the area of insulin delivery systems. It also has a leading position in areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×